Bottomley S S, May B K, Cox T C, Cotter P D, Bishop D F
Department of Medicine, University of Oklahoma College of Medicine, Oklahoma City 73104, USA.
J Bioenerg Biomembr. 1995 Apr;27(2):161-8. doi: 10.1007/BF02110031.
The erythroid-specific isozyme of 5-aminolevulinate synthase (ALAS2), the first and rate-limiting enzyme of heme biosynthesis, is expressed concomitantly with the differentiation and maturation of the erythroid cell in order to accommodate generation of the large amounts of heme required for hemoglobin production. During the past few years the ALAS2 gene and its transcript have been characterized and the amino acid sequence of the enzyme deduced. The human genetic disorder X-linked sideroblastic anemia, previously postulated to be caused by defects of ALAS, has now been analyzed at the molecular and tissue-specific level. A heterogeneous group of point mutations in the catalytic domain of the ALAS2 enzyme has been found to cause the disorder. Impaired activity of recombinant mutant ALAS2 enzymes has also been demonstrated. Characterization of molecular defects in individuals with X-linked sideroblastic anemia has provided improved diagnosis for at-risk family members.
5-氨基酮戊酸合酶(ALAS2)的红系特异性同工酶是血红素生物合成的首个限速酶,它随着红系细胞的分化和成熟而表达,以满足血红蛋白生成所需大量血红素的合成。在过去几年里,已对ALAS2基因及其转录本进行了表征,并推导了该酶的氨基酸序列。人类遗传性疾病X连锁铁粒幼细胞贫血,此前推测由ALAS缺陷所致,现在已在分子和组织特异性水平上进行了分析。已发现ALAS2酶催化结构域中的一组异质性点突变可导致该疾病。重组突变ALAS2酶的活性受损也已得到证实。对X连锁铁粒幼细胞贫血患者分子缺陷的表征为高危家庭成员提供了更好的诊断方法。